Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on March 10, 2022. The filing announces the reporting of financial results for the three and twelve months ended December 31, 2021, along with recent corporate updates. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K document.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms that results for the three and twelve months ended December 31, 2021, have been reported.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933 and shall not be deemed incorporated by reference into other SEC filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the correct registrant name is Salarius Pharmaceuticals, Inc. (Ticker: SLRX), as the input metadata incorrectly listed Decoy Therapeutics Inc.
- Review Exhibit 99.1 (the Press Release) to obtain actual financial figures for the three and twelve months ended December 31, 2021.
- Confirm that the financial data in the press release is not automatically incorporated by reference into other filings due to the specific disclaimer in Item 2.02.
- Check the Nasdaq Capital Market listing status for SLRX as indicated in the filing.